Dr. Reddy's closes on acquisition of smoking cessation Habitrol brand

HYDERABAD, India — Dr. Reddy’s Laboratories has announced that it has closed the acquisition of Habitrol brand — an over-the-counter nicotine replacement therapy transdermal patch — from Novartis Consumer Health following issuance of the proposed consent order from the U.S. Federal Trade Commission on Nov. 26. 

 

The company had earlier entered into an asset purchase agreement with Novartis Consumer Health to acquire the title and rights of Habitrol brand and to market the product in the U.S. market.

 

With this closure, the company has assumed responsibility for the product and will commence shipments of the product in the market shortly.